Retrophin Inc (NASDAQ:RTRX) COO Neil F. Mcfarlane sold 1,968 shares of the stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $18.25, for a total value of $35,916.00. Following the completion of the sale, the chief operating officer now directly owns 27,972 shares of the company’s stock, valued at $510,489. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
NASDAQ RTRX traded up $0.44 on Friday, hitting $19.01. 412,622 shares of the stock traded hands, compared to its average volume of 373,252. Retrophin Inc has a 12 month low of $17.53 and a 12 month high of $33.00. The firm has a market cap of $769.48 million, a price-to-earnings ratio of -7.48 and a beta of 0.91. The company has a current ratio of 4.57, a quick ratio of 4.52 and a debt-to-equity ratio of 0.69.
Retrophin (NASDAQ:RTRX) last announced its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.41). Retrophin had a negative net margin of 75.75% and a negative return on equity of 41.38%. The firm had revenue of $39.57 million for the quarter, compared to the consensus estimate of $41.40 million. During the same period last year, the company posted ($0.14) earnings per share. Retrophin’s revenue for the quarter was up 3.0% on a year-over-year basis. Analysts forecast that Retrophin Inc will post -3.02 EPS for the current year.
A number of hedge funds and other institutional investors have recently made changes to their positions in RTRX. Bank of America Corp DE boosted its holdings in shares of Retrophin by 114.4% in the fourth quarter. Bank of America Corp DE now owns 1,223,705 shares of the biopharmaceutical company’s stock worth $27,693,000 after acquiring an additional 652,895 shares during the period. Macquarie Group Ltd. boosted its holdings in shares of Retrophin by 17.6% in the fourth quarter. Macquarie Group Ltd. now owns 2,265,924 shares of the biopharmaceutical company’s stock worth $51,278,000 after acquiring an additional 339,588 shares during the period. Two Sigma Investments LP boosted its holdings in shares of Retrophin by 247.9% in the fourth quarter. Two Sigma Investments LP now owns 300,873 shares of the biopharmaceutical company’s stock worth $6,809,000 after acquiring an additional 214,392 shares during the period. Opaleye Management Inc. bought a new position in shares of Retrophin in the first quarter worth $4,639,000. Finally, J. Goldman & Co LP bought a new position in shares of Retrophin in the first quarter worth $4,550,000.
Several analysts have recently commented on the company. Zacks Investment Research downgraded Retrophin from a “hold” rating to a “sell” rating in a research note on Tuesday. Barclays assumed coverage on Retrophin in a research note on Monday, April 22nd. They issued an “overweight” rating and a $36.00 price objective for the company. BidaskClub downgraded Retrophin from a “sell” rating to a “strong sell” rating in a research note on Friday, April 19th. William Blair reissued an “outperform” rating on shares of Retrophin in a research note on Wednesday, April 17th. Finally, ValuEngine downgraded Retrophin from a “buy” rating to a “hold” rating in a research note on Thursday, April 18th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the stock. Retrophin currently has a consensus rating of “Hold” and an average target price of $45.67.
ILLEGAL ACTIVITY WARNING: “Retrophin Inc (RTRX) COO Neil F. Mcfarlane Sells 1,968 Shares” was originally published by Macon Daily and is the property of of Macon Daily. If you are reading this piece on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this piece can be read at https://macondaily.com/2019/05/17/retrophin-inc-rtrx-coo-neil-f-mcfarlane-sells-1968-shares.html.
Retrophin, Inc, a biopharmaceutical company, focuses on the identification, development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.
Featured Article: Convertible Shares
Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.